Dietary recommendations for dysbetalipoproteinemia: A need for better evidence.
J Clin Lipidol
; 17(4): 549-556, 2023.
Article
em En
| MEDLINE
| ID: mdl-37268489
ABSTRACT
The increased risk of cardiovascular disease in patients with dysbetalipoproteinemia (DBL) is well documented and is associated with the dysfunctional metabolism of remnant lipoproteins. Although these patients are known to respond well to lipid-lowering medication including statins and fibrates, the best dietary approach to lower remnant lipoprotein accumulation and to prevent cardiovascular outcomes remain unclear. Indeed, current evidence is based on studies published mainly in the 1970s, which comprise small sample sizes and methodological limitations. This review aims to summarize nutritional studies performed in DBL patients to date and to discuss potential avenues in this field and future areas of research.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doenças Cardiovasculares
/
Inibidores de Hidroximetilglutaril-CoA Redutases
/
Hiperlipoproteinemia Tipo III
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article